Richard Drachtman, clinical section chief of the Pediatric Hematology/Oncology Division at Rutgers Cancer Institute of New Jersey, received the 2018 recipient of the Melvyn H. Motolinsky Research Foundation Distinguished Service Award in recognition of his accomplishments and leadership in the field of pediatric cancer and blood disorders.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
